# HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

> **NCT04486651** · PHASE3 · UNKNOWN · sponsor: **Taizhou Hanzhong biomedical co. LTD** · enrollment: 560 (estimated)

## Conditions studied

- Stomach Cancer

## Interventions

- **DRUG:** Irinotecan Hydrochloride Injection
- **DRUG:** HX008
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04486651
- **Lead sponsor:** Taizhou Hanzhong biomedical co. LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-16
- **Primary completion:** 2023-08-10
- **Final completion:** 2023-08-10
- **Target enrollment:** 560 (ESTIMATED)
- **Last updated:** 2021-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04486651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04486651, "HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04486651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*